The tweet was deleted by the author.
But we saved everything 🙂.
Gilead Sciences has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases.
This strategic move aims to bolster Gilead Sciences presence in the rapidly evolving autoimmune disease treatment landscape. Ouro Medicines brings a pipeline of innovative therapies targeting immune system disorders, underscoring Gilead Sciences commitment to diversifying its biopharmaceutical portfolio. Financial terms of the transaction were not disclosed.
Gilead Sciences has recently advanced HIV prevention initiatives by leveraging music and community engagement at SXSW, as detailed in recent coverage. The company also began a crossover clinical trial targeting metastatic triple negative breast cancer, according to a separate report. These efforts reflect a continued focus on expanding Gilead’s research and development across multiple disease areas.